about
New heparin dosing recommendations for patients with acute coronary syndromesDetermination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFEfficacy of abciximab readministration in coronary intervention.Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium.Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists.Preclinical differentiation of low molecular weight heparins.Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.Antithrombotic therapy after prosthetic cardiac valve implantation: potential novel antithrombotic therapies.Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism TrHigher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanHospitalizations in patients with atrial fibrillation: an analysis from ROCKET AFComplication rates after hip or knee arthroplasty in morbidly obese patientsOral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplastyThe discovery and development of rivaroxaban.Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.The discovery of rivaroxaban: translating preclinical assessments into clinical practice.Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial.Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.Cardiovascular drug development: is it dead or just hibernating?Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.Novel oral anticoagulants and reversal agents: Considerations for clinical development.Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy.Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial.
P50
Q28184399-9A1808D3-16CC-4D03-A251-4406FFB103B8Q28193322-E5F8FB7A-CC6D-445B-B4A9-DB321B984205Q31054764-2A44C7C8-0B5A-497F-8158-686AC37D8C31Q33331867-4245CDE0-21A6-43D6-9A38-D81C8C02CBA5Q33335727-31BA1C1E-D46F-464F-B8A2-FAE4648F06DBQ33336772-9AF7D3E1-D205-4878-BCD4-54E2C0BEC6EDQ33498609-A494DD11-EA68-4BB3-AB5D-1EB699303550Q33501187-4DA31A6D-7AD7-4FE1-9ADB-78DD337472DFQ33671190-8DA8A1A2-1BE2-44C6-B34B-3806BA935B9FQ33723270-4D9ABF7A-C3EA-46E6-A6D7-96FAB7103CD9Q33767642-981B9BF0-B2FE-483D-9E54-354043CB8079Q33823899-C74B2EE1-FD71-4CF1-BE52-02DBFA3D2D92Q33973552-102F1E24-9225-4362-9010-8DFF9C7A10FDQ34142415-61F68167-717A-4E1C-B321-94894D30861EQ34296242-88B2100E-DDE4-4621-91FA-9E613299325BQ34388959-74B9B18C-605A-4DF2-AA05-69CF088DB507Q34607209-7D6A4F8A-533E-462A-828B-19074C5C56F1Q34668487-3F133D40-4F6C-45E8-9962-3CDE7BFABFE4Q35036404-0C26D454-8EDD-4126-B6CF-573B8C0592A4Q35114692-CD0BD2B5-A136-4170-A8F3-6F687B14C65FQ37085638-400879AE-CC8E-43BB-8252-97E69148728EQ37153930-F9C6BC7B-9FB1-4059-8C23-4F939A7C904AQ37170842-A21BDA52-03A6-4F51-B15E-81636F64D18FQ37363885-F0873C2C-A3A4-4899-8001-47D873507FC9Q37677976-4CA50E3C-C439-4B19-A103-D4083074AAB9Q37857332-BBD42631-F126-4B85-A7E0-242E9088D09CQ38108855-698A7911-AD1F-4C8D-B459-88241322AF42Q38170106-3A5D8593-A9FB-4EC9-8BEB-8D1B7E65EDC3Q38375586-E4C91B41-3354-4EA3-85DD-D02DD2C1EC42Q38377660-F3D2D716-444C-41F4-8110-D7966D9E5BE1Q38398409-E8D9AC92-5A2E-4880-8666-5235745272DCQ38424497-B6A3C527-BE01-4923-883D-F60B33864A7DQ38431555-7C5CB00F-32A3-4A20-92F6-7CFEC670D1A7Q38450691-8D4D3DD2-53F5-4624-8535-A2FDEFE691CAQ38509194-AB2D4F93-0727-41A5-B93E-B6469DA38E2FQ38740354-F100B0BB-9B11-401E-9C20-4FCB4DA99626Q39472608-26921FBB-81D9-498D-A0C2-29DC82A27B4BQ40286342-5DD500F1-173E-435D-8090-3231969B9926Q40594662-30AEEAE9-0416-4F87-8F0A-7E7903985987Q40630369-62A3D428-DE96-4026-B3D2-A2E91D9C3EFE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Scott D Berkowitz
@ast
Scott D Berkowitz
@en
Scott D Berkowitz
@es
Scott D Berkowitz
@nl
Scott D Berkowitz
@sl
type
label
Scott D Berkowitz
@ast
Scott D Berkowitz
@en
Scott D Berkowitz
@es
Scott D Berkowitz
@nl
Scott D Berkowitz
@sl
prefLabel
Scott D Berkowitz
@ast
Scott D Berkowitz
@en
Scott D Berkowitz
@es
Scott D Berkowitz
@nl
Scott D Berkowitz
@sl
P106
P21
P31
P496
0000-0002-9428-4408